undamentalytics Newsletter
Sign in

Senti Biosciences Holdings, Inc. balance sheet

At the end of fiscal 2025, Senti Biosciences Holdings, Inc. had total assets of $51.2m, total liabilities of $45.6m and shareholders' equity of $5.6m. It held $16.4m in cash against $0 of debt: net cash of $16.4m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents5658364816
Receivables01———
Total current assets60103715923
Total assets971811199851
Accounts payable51113
Deferred revenue (current)21000
Total current liabilities1518131314
Total debt00000
Total liabilities3654534746
Shareholders' equity−11112767266
Non-controlling interests and other (assets − liabilities − equity)172——25—
Net debt (negative = net cash)−56−58−36−48−16
Shares outstanding——23m24m—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Senti Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Senti Biosciences Holdings, Inc.